Preclinical Histology Workflow within NANBIOSIS
New video shows the Preclinical Histology workflow of NANBIOSIS Unit 20 at VHIR, part of an integrated platform for preclinical validation and imaging.
NANBIOSIS has published a new video on its YouTube channel showcasing the Preclinical Histology Section, one of the key service areas of NANBIOSIS Unit 20 – In vivo Experimental Platform, located at the Vall d’Hebron Research Institute (VHIR) in Barcelona.
The Preclinical Histology Section provides specialized tissue processing and staining services for the evaluation of therapeutic compounds and biomarkers in preclinical research. Operating within ISO-certified facilities, the team works with both paraffin-embedded and OCT-embedded frozen samples, offering high-level expertise in histological staining, immunohistochemistry, and immunofluorescence.
The video focuses on the paraffin-embedded sample workflow, demonstrating each step of the process: reception and classification of formalin-fixed samples, automated tissue processing, paraffin embedding, precise block orientation, microtome sectioning, and hematoxylin–eosin staining. The section routinely handles a wide range of biological materials, from whole organs to delicate tissues and advanced 3D models such as organoids, ensuring reproducibility and high-quality results.
Importantly, the Preclinical Histology Section is part of the broader NANBIOSIS Unit 20, which comprises three integrated sections: Molecular Imaging, Preclinical Animal Models, and Preclinical Histology. All three are embedded within the Functional Validation & Preclinical Research (FVPR) area of CIBBIM-Nanomedicine. This integrated structure enables Unit 20 to offer comprehensive preclinical proof-of-concept validation services.
Led by Dr. Ibane Abasolo, Head of FVPR, Unit 20 stands out for combining toxicology, histopathology, and efficacy studies with non-invasive optical imaging technologies, including in vivo bioluminescence and fluorescence imaging. This unique combination allows longitudinal monitoring of living animal models, providing real-time insights into treatment efficacy, biodistribution, and mechanisms of action. While similar imaging technologies exist elsewhere in Spain, Unit 20 is unique in offering them fully integrated with dedicated preclinical animal models.
This new video offers a practical glimpse into the high-quality preclinical services available through NANBIOSIS Unit 20.
More information about the unit and its full service portfolio is available on the NANBIOSIS website.
https://www.youtube.com/shorts/PwYuCOJALlE
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
If you want to collaborate with us, visit our Open Call page.
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
